Nat Rev Rheumatol . 2018 Jul;14(7):421-432. doi: 10.1038/s41584-018-0021-9.

Existing and Novel Biomarkers for Precision Medicine in Systemic Sclerosis

Peter J Wermuth  ^{1   2} , Sonsoles Piera-Velazquez  ^{1   2} , Joel Rosenbloom  ^{1   2} , Sergio A Jimenez  ^{3   4   5}

Abstract

The discovery and validation of biomarkers resulting from technological advances in the analysis of genomic, transcriptomic, lipidomic and metabolomic pathways involved in the pathogenesis of complex human diseases have led to the development of personalized and rationally designed approaches for the clinical management of such disorders. Although some of these approaches have been applied to systemic sclerosis (SSc), an unmet need remains for validated, non-invasive biomarkers to aid in the diagnosis of SSc, as well as in the assessment of disease progression and response to therapeutic interventions. Advances in global transcriptomic technology over the past 15 years have enabled the assessment of microRNAs that circulate in the blood of patients and the analysis of the macromolecular content of a diverse group of lipid bilayer membrane-enclosed extracellular vesicles, such as exosomes and other microvesicles, which are released by all cells into the extracellular space and circulation. Such advances have provided new opportunities for the discovery of biomarkers in SSc that could potentially be used to improve the design and evaluation of clinical trials and that will undoubtedly enable the development of personalized and individualized medicine for patients with SSc.